Trials / Completed
CompletedNCT04362748
Study of AMG 256 in Adult Subjects With Advanced Solid Tumors
A Phase 1 Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 256 in Patients With Advanced Solid Tumors
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 34 (actual)
- Sponsor
- Amgen · Industry
- Sex
- All
- Age
- 18 Years – 100 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the safety and tolerability of AMG 256 in adult participants and to determine the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AMG 256 | AMG 256 administered as an intravenous (IV) infusion. |
Timeline
- Start date
- 2020-09-15
- Primary completion
- 2023-09-21
- Completion
- 2023-09-21
- First posted
- 2020-04-27
- Last updated
- 2025-10-07
Locations
11 sites across 4 countries: United States, Australia, Belgium, Spain
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04362748. Inclusion in this directory is not an endorsement.